Condition (MeSH)
Immune Complex Diseases
ClinicalTrials.gov lists 38 trials for Immune Complex Diseases or a narrower condition beneath it. Cogent Biosciences, Inc. has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
3 of the 38 trials are tagged with Immune Complex Diseases itself; the rest are tagged with a narrower condition beneath it.
When did Immune Complex Diseases trials start? (19)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 2
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 5
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2026 (partial year) | 2 |
| 2025 | 2 |
| 2023 | 3 |
| 2022 | 2 |
| 2021 | 3 |
| 2020 | 2 |
| 2019 | 2 |
| 2018 | 1 |
| 2017 | 3 |
| 2016 | 2 |
Showing 10 of 19 earlier years.
No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 4 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Immune Complex Diseases trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 2 | 9 |
| Phase 3 | 3 |
| Phase 4 | 3 |
| Not applicable | 7 |
| Observational | 16 |
How many Immune Complex Diseases trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Not yet recruiting | 1 |
| Recruiting | 12 |
| Active, not recruiting | 1 |
| Completed | 15 |
| Terminated | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Immune Complex Diseases trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Cogent Biosciences, Inc. | 2 |
| Alexion Pharmaceuticals, Inc. | 1 |
| Bursa City Hospital | 1 |
Which drugs are being tested for Immune Complex Diseases? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| METHYLPREDNISOLONE | 3 |
| Bezuclastinib | 2 |
| RITUXIMAB | 2 |
| Cytoxan | 2 |
| Dapsone | 2 |
Interventions as named in the registry (10)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Colchicines | 2 |
| Autologous Peripheral Blood Stem Cell Transplantation | 1 |
| BLOOD SAMPLES | 1 |
| Gamma Globulin | 1 |
| INFLUENZA VACCINE | 1 |
Showing 5 of 10 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Immune Complex Diseases trials report? (8)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Cellulitis | 1 | 1 |
| Myocardial infarction | 1 | 1 |
| Oral candidiasis | 1 | 1 |
| Polychondritis | 1 | 1 |
| Septic shock | 1 | 1 |
Showing 5 of 8 adverse events.
Which publications cover Immune Complex Diseases? (12)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Immune complex disease in a chronic monkey study with a humanised, therapeutic antibody against CCL20 is associated with complement-containing drug aggregates. | PloS one | 2020 | Yes |
| Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complex-Mediated Membranoproliferative GN. | Journal of the American Society of Nephrology : JASN | 2018 | Yes |
| Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery. | Trends in immunology | 2017 | Yes |
| Paraffin immunofluorescence in the renal pathology laboratory: more than a salvage technique. | Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc | 2015 | Yes |
| Morphologic features of extrahepatic manifestations of hepatitis C virus infection. | Clinical & developmental immunology | 2012 | Yes |
Showing 5 of 12 publications.
Sub-conditions in MeSH (2)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence and rare-disease identity.